A phase II dose-ranging study of mirabegron in patients with overactive bladder

详细信息    查看全文

• 作者：Christopher R. Chapple (1)
  Vladimir Dvorak (2)
  Pjotr Radziszewski (3)
  Philip Van Kerrebroeck (4)
  Jean Jacques Wyndaele (5)
  Brigitte Bosman (6)
  Peter Boerrigter (6)
  Ted Drogendijk (6)
  Arwin Ridder (6)
  Ingrid Van Der Putten-Slob (6)
  Osamu Yamaguchi (7)
  
• 关键词：β3 ; adrenoceptor agonist ; Mirabegron ; Overactive ; Urinary bladder
• 刊名：International Urogynecology Journal
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：24
• 期：9
• 页码：1447-1458
• 全文大小：221KB
• 参考文献：1. Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP et al (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 103 [Suppl 3]:12-3 CrossRef
  2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2003) The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urol 61:37-9 CrossRef
  3. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-78 CrossRef
  4. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R (2008) Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 14:291-01
  5. Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276-282 CrossRef
  6. Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y et al (1999) Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819-25 CrossRef
  7. Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T et al (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367-373
  8. Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y et al (1999) Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 161:680-85 CrossRef
  9. Nomiya M, Yamaguchi O (2003) A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170:649-53 CrossRef
  10. Kumar V, Templeman L, Chapple CR, Chess-Williams R (2003) Recent developments in the management of detrusor overactivity. Curr Opin Urol 13:285-91 CrossRef
  11. Cartwright R, Srikrishna S, Cardozo L, Robinson D (2011) Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder. BJU Int 107:1612-617 CrossRef
  12. Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C et al (1996) The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 77:554-62 CrossRef
  13. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P (1996) The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 77:805-12 CrossRef
  14. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563-74 CrossRef
  15. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin (2006) Stat Med 25:1628-638
  16. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543-62 CrossRef
  17. Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ et al (2011) Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 6:e16718 CrossRef
  18. Novara G, Galfano A, Secco S, D'Elia C, Cavalleri S, Ficarra V et al (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740-63 CrossRef
  19. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev CD003781
  20. Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS (2010) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 106:268-74 CrossRef
  21. Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L (2008) Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50?years. J Cardiovasc Pharmacol Ther 13:241-51 CrossRef
  
• 作者单位：Christopher R. Chapple (1)
  Vladimir Dvorak (2)
  Pjotr Radziszewski (3)
  Philip Van Kerrebroeck (4)
  Jean Jacques Wyndaele (5)
  Brigitte Bosman (6)
  Peter Boerrigter (6)
  Ted Drogendijk (6)
  Arwin Ridder (6)
  Ingrid Van Der Putten-Slob (6)
  Osamu Yamaguchi (7)
  
  1. Department of Urology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Glossop Road, Sheffield, S10 2JF, UK
  2. Centrum ambulantní gynekologie a primární péce, Brno, Czech Republic
  3. Department of Urology, Medical University Warsaw, Warsaw, Poland
  4. Department Urology, Maastricht University Medical Center, Maastricht, The Netherlands
  5. Department of Urology, Antwerp University and Antwerp University Hospital, Antwerp, Belgium
  6. Astellas Pharma Europe BV, Leiden, The Netherlands
  7. Division of Bioengineering and LUTD Research, School of Engineering, Nihon University, Koriyama, Japan
  

文摘

Introduction and hypothesis Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Methods Patients completed a single-blinded, 2-week placebo run-in period followed by 12?weeks of randomized (n--28) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200?mg once-daily (QD), placebo or tolterodine extended release (ER) 4?mg QD. The primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes/24?h. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes/24?h; severity of urgency; nocturia; and quality of life measures. Safety parameters included vital signs, adverse events, laboratory tests, electrocardiogram measurements and post-void residual volume. Results Mirabegron 25, 50, 100, and 200?mg resulted in dose-dependent reductions (improvements) from baseline to end-of-treatment in micturition frequency of 1.9, 2.1, 2.1, and 2.2 micturitions/24?h respectively, versus 1.4 micturitions/24?h with placebo (p?≤-.05 for the mirabegron 50-, 100-, and 200-mg comparisons). There was a statistically significant improvement with mirabegron compared with placebo for most secondary endpoints including quality of life variables. While there was a significant (p-lt;-.05) increase from baseline in pulse rate in the mirabegron 100-mg and 200-mg groups, this was not associated with an increased incidence of cardiovascular adverse events. Conclusions The favorable efficacy and tolerability of mirabegron in this phase II dose-finding study has led to its successful advancement into a phase III clinical development program.